FDA Approves Datopotamab Deruxtecan-dlnk for Unresectable or Metastatic, Hormone Receptor-positive, HER2-negative Breast Cancer By Ogkologos - February 27, 2025 308 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the TROPION-Breast01 study Source RELATED ARTICLESMORE FROM AUTHOR Advanced and metastatic prostate cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up PAXG Significantly Improves EFS Compared with mFOLFIRINOX in Patients with Resectable or Borderline Resectable Pancreatic Ductal Adenocarcinoma EMA Recommends Extension of Therapeutic Indications for Retifanlimab MOST POPULAR How International Collaboration Has Helped Improve Cancer Care in Nepal April 8, 2021 FDA Approves Bosutinib for Paediatric Patients with Chronic Myelogenous Leukaemia October 13, 2023 One Year in Cancer Research and Much to Celebrate December 20, 2024 Rare Disease Day: Raising Awareness for Rare Cancers February 26, 2021 Load more HOT NEWS Discovery of Tumor Suppressor Suggests New Cancer Treatment Strategies FDA Approves Tepotinib for Metastatic Non-Small Cell Lung Cancer Fostering Growth and Creativity Through Journaling Reused, Reheated Cooking Oil May Trigger Breast Cancer Progression, Metastasis
